Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma
09:23am, Tuesday, 17'th Aug 2021
CAMBRIDGE, Mass. & BEIJING & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Admi
BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients
07:43am, Friday, 30'th Jul 2021
BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to bendamustine and rituximab (B+R). The trial
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company, today announced positive topline results
Why BeiGene Stock Soared Today
03:52pm, Wednesday, 28'th Jul 2021
A regulatory filing gave a sneak peek at the company's second-quarter sales.
BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
09:38am, Monday, 26'th Jul 2021
Health Canada has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy. This is
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
07:00am, Monday, 26'th Jul 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable m
BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients
06:16am, Friday, 09'th Jul 2021
The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The approval covers Kyprolis in combina
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple M
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinom
PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer
11:30am, Wednesday, 07'th Jul 2021
PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership will evaluate BeiGene's tislelizumab, in co
Is This Chinese Biopharma Stock Still a Buy?
11:31am, Monday, 28'th Jun 2021
The pharmaceutical company had a solid first quarter and boasts a nice pipeline.
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
12:00am, Wednesday, 23'rd Jun 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines wo
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines wo
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
04:20pm, Sunday, 13'th Jun 2021
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
10:15am, Friday, 11'th Jun 2021
BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibrutinib) for relapsed or ref
